About Our Publications

Because we work under CDAs most of our work cannot be published.

Fortunately, some recent projects in which our CEO participated have been published and are presented here.

Publications

DNA launched suicidal flaviviruses as therapeutic vaccine candidates

Research background
Chronic liver disease, resulting from Hepatitis B virus (HBV), Hepatitis D virus (HDV), or Hepatitis
C virus (HCV) infections, contributes to a major health burden worldwide. The relatively high
cost of the HCV treatment brings concerns about the accessibility, especially in the developing
countries. Hence, there exists a need for cost effect interventions with high efficiency. The use
of DNA prime-viral vector has been validated in prime-boost vaccination. The use of Flavivirus
subgenomic replicons as DNA based vaccine will provide excellent stability and high expression
of the vaccine candidate genes in combination with immune activation…..

read more

Mass spectrometry of macromolecules

Data on the use of accelerator mass spectrometry (AMS) in conjunction with in vivo studies of macromolecular drugs are scarce. The present study shows the versatility of this technique when investigating the pharmacokinetics (PK) of a macromolecular drug candidate, a...

read more

Multigene HIV vaccine

It is likely that gene-based vaccines will enter the human vaccine area soon. A few veterinary vaccines employing this concept have already been licensed, and a multitude of clinical trials against infectious diseases or different forms of cancer are ongoing. Highly...

read more

In vivo electroporation

The mechanisms by which in vivo electroporation (EP) improves the potency of i.m. DNA vaccination were characterized by using the hepatitis C virus nonstructural (NS) 3/4A gene. Following a standard i.m. injection of DNA with or without in vivo EP, plasmid levels...

read more

Interesting Reading